American Journal of Kidney Diseases
Volume 49, Issue 2 , Pages 186-193, February 2007

Risks of Proteinuria and Hypertension With Bevacizumab, an Antibody Against Vascular Endothelial Growth Factor: Systematic Review and Meta-Analysis

Divisions of Nephrology and Oncology, SUNY at Stony Brook, NY: Medical Oncology Branch, National Cancer Institute, Bethesda, MD; and Section of Nephrology, Yale University and VAMC, West Haven, CT.

Received 18 July 2006; accepted 9 November 2006. published online 02 January 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Originally published online as doi:10.1053/j.ajkd.2006.11.039 on January 5, 2007.Support: None. Potential conflicts of interest: None.

PII: S0272-6386(06)01833-6

doi:10.1053/j.ajkd.2006.11.039

American Journal of Kidney Diseases
Volume 49, Issue 2 , Pages 186-193, February 2007

Article Tools

* Image Usage & Resolution